Best in Biotech 5 Aug 2025 10 oncology deals in 2025 spotlight where industry leaders are betting big …payments through 2028, and up to $7.6 billion in milestone payments. The partnership involves the co-development and co-commercialization of BioNTech’s investigational bispecific antibody BNT327 across numerous solid tumor types, as… August 5, 2025 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Weekly Roundup 10 Nov 2023 Korro Bio and Frequency’s merger; Lexeo’s $100 million IPO; Gate Biosciences new class of drugs …lead product candidate in alpha-1 antitrypsin deficiency (AATD) through a clinical milestone, progression of additional product candidates from the pipeline into the clinic, and demonstrating applicability of the RNA editing… November 10, 2023 - 12 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jul 2025 Serial acquirer Concentra Biosciences on a buyout spree in 2025 …proceeds from its candidates KB-9558 and KB-7898 to treat cancer and autoimmune conditions, respectively, over the next two years. Plus, it includes all of the proceeds from its candidates KB-0742,… July 15, 2025 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 4 Dec 2024 Idiopathic pulmonary fibrosis: Refoxy, Boehringer, Insilico, and more on the hunt for curative treatments …candidate One promising candidate is Refoxy Pharma’s FOXO3 therapy. The Cologne-based biotech made the news this morning after it secured €9.1 million ($9.58 million) in a financing round led by… December 4, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 6 Oct 2022 15 biotech companies shaking up the scene in Cambridge …major biotech and pharma hub. Antibody development is one of the strengths of the city thanks to the legacy of Cambridge Antibody Technologies, which pioneered the technology of phage display… October 6, 2022 - 9 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Best in Biotech 8 May 2019 Top 10 Biotechs in Lausanne …discontinuing two phase III trials testing AC Immune’s lead antibody drug candidate as an Alzheimer’s treatment. However, the candidate is still in an ongoing phase II trial for the prevention… May 8, 2019 - 7 minutesmins - By David Cox Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2022 Ophthalmology biopharma company Oculis combines with EBAC …Other candidates In addition to these three clinical candidates, Oculis is engaged in several earlier preclinical development initiatives, including the evaluation of OCS-03 as a possible treatment for corneal neovascularization,… October 17, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2022 Poolbeg identifies new potential drug candidates for RSV infections Poolbeg Pharma says it has successfully identified potential new drug candidates from its respiratory syncytial virus (RSV) artificial intelligence (AI) program with OneThree Biotech, Inc. Since initiating the collaboration in… December 21, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2022 Poolbeg to investigate melioidosis vaccine candidate Poolbeg Pharma has signed an exclusive agreement with University College Dublin (UCD) through NovaUCD, the university’s knowledge transfer office, for a late preclinical stage vaccine candidate for melioidosis, a disease… September 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 May 2023 Scientists create first CRISPR-based drug candidate targeting the microbiome A new CRISPR-based drug candidate targeting E. coli in the gut microbiome is in phase 1 clinical trials. According to a new paper published in Nature Biotechnology, it may improve… May 10, 2023 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 20 Feb 2024 Biotechs in the US Capital: seven key players based in Washington DC …to specific genetic variants in the IGHMBP2 gene. The second candidate, VTR-297, is a novel topical antifungal candidate aimed at treating onychomycosis. This condition, affecting up to 14% of the… February 20, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jul 2022 Companies come together in fight against Dengue Fever …vaccine candidate. The agreement initially focuses on Emergex’s dengue vaccine candidate and also includes the shared development and commercialization of COVID-19 and Chikungunya vaccine candidates. Emergex’s Dengue and COVID-19 vaccine… July 1, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email